CINECA IRIS Institutional Research Information System

DI NICOLANTONIO, Federica
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 16.374
EU - Europa 12.367
AS - Asia 10.163
SA - Sud America 490
OC - Oceania 278
AF - Africa 124
Continente sconosciuto - Info sul continente non disponibili 32
Totale 39.828
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 15.691
CN - Cina 5.928
IT - Italia 3.872
GB - Regno Unito 1.213
DE - Germania 1.162
JP - Giappone 1.006
FR - Francia 965
IE - Irlanda 668
RU - Federazione Russa 567
ES - Italia 543
SG - Singapore 541
SE - Svezia 515
KR - Corea 514
CA - Canada 499
IN - India 465
NL - Olanda 419
FI - Finlandia 416
PL - Polonia 398
HK - Hong Kong 373
TW - Taiwan 309
UA - Ucraina 255
BE - Belgio 231
TR - Turchia 231
AU - Australia 228
VN - Vietnam 202
CH - Svizzera 201
BR - Brasile 162
GR - Grecia 159
MX - Messico 152
DK - Danimarca 146
AT - Austria 141
IL - Israele 98
RO - Romania 94
TH - Thailandia 84
PE - Perù 81
PT - Portogallo 79
CO - Colombia 75
HU - Ungheria 67
CZ - Repubblica Ceca 66
NO - Norvegia 66
AR - Argentina 63
IR - Iran 52
CL - Cile 51
NZ - Nuova Zelanda 49
SA - Arabia Saudita 43
ID - Indonesia 41
MY - Malesia 36
EC - Ecuador 34
JO - Giordania 29
AM - Armenia 28
SN - Senegal 28
PH - Filippine 27
PK - Pakistan 20
EG - Egitto 17
EU - Europa 17
LB - Libano 17
HR - Croazia 16
MO - Macao, regione amministrativa speciale della Cina 16
NG - Nigeria 16
SK - Slovacchia (Repubblica Slovacca) 16
KZ - Kazakistan 15
AE - Emirati Arabi Uniti 14
TN - Tunisia 14
MA - Marocco 13
SI - Slovenia 13
PS - Palestinian Territory 12
ZA - Sudafrica 12
BA - Bosnia-Erzegovina 11
PR - Porto Rico 11
RS - Serbia 11
UZ - Uzbekistan 11
GY - Guiana 10
AP - ???statistics.table.value.countryCode.AP??? 9
BY - Bielorussia 8
CY - Cipro 8
DZ - Algeria 8
QA - Qatar 8
BG - Bulgaria 7
BN - Brunei Darussalam 7
EE - Estonia 7
LU - Lussemburgo 7
LV - Lettonia 7
GH - Ghana 6
NI - Nicaragua 6
UY - Uruguay 6
AL - Albania 5
BD - Bangladesh 5
ET - Etiopia 5
IS - Islanda 5
KH - Cambogia 5
LT - Lituania 5
PA - Panama 5
BO - Bolivia 4
HN - Honduras 4
IQ - Iraq 4
VE - Venezuela 4
A1 - Anonimo 3
A2 - ???statistics.table.value.countryCode.A2??? 3
LK - Sri Lanka 3
MK - Macedonia 3
Totale 39.802
Salva come PNG Salva come JPEG
Città #
Ann Arbor 2.552
Beijing 1.254
Chandler 940
Fairfield 818
Houston 799
Shanghai 741
Redwood City 624
Dublin 622
Torino 539
Ashburn 474
Guangzhou 459
Woodbridge 453
Seattle 436
Wilmington 433
Hangzhou 413
Cambridge 390
Dearborn 376
Singapore 365
Milan 305
Nanjing 264
Tokyo 254
Turin 236
Villeurbanne 236
New York 229
Pisa 216
Warsaw 191
Nyköping 179
Boston 171
Jacksonville 171
Princeton 170
Medford 155
Taipei 155
Wuhan 155
Rome 153
Lappeenranta 129
Barcelona 126
London 126
Chengdu 120
Paris 111
San Diego 108
Los Angeles 106
Toronto 104
Dong Ket 103
Fremont 103
Seoul 100
Shenzhen 97
Buffalo 94
Boardman 93
Shenyang 91
Brussels 89
Berlin 87
Vienna 87
Amsterdam 82
Ottawa 82
Changsha 76
Tianjin 76
Duncan 75
Munich 74
Chicago 73
Zhengzhou 73
Central District 72
Chongqing 72
Central 71
Santa Clara 70
Jinan 67
Helsinki 65
Xian 64
Phoenix 60
Hong Kong 58
Lima 58
Madrid 57
Istanbul 56
Genoa 53
San Francisco 53
Utrecht 52
Washington 52
Bologna 51
Kunming 50
Carrara 48
Daejeon 46
Falls Church 46
Norwalk 46
Manchester 44
Pune 44
Rochester 44
Dundee 43
Zurich 43
Bangkok 42
Hyderabad 42
Philadelphia 42
Silver Spring 42
Bengaluru 41
Fuzhou 41
Harbin 41
Nanchang 41
Ankara 40
Melbourne 40
Naples 40
Stuttgart 40
Sydney 40
Totale 20.430
Salva come PNG Salva come JPEG
Nome #
High-dose Vitamin C enhances cancer immunotherapy 4.321
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR 3.917
Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma. 2.148
Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth 1.795
Adaptive mutability of colorectal cancers in response to targeted therapies 1.710
ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer 1.320
MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations 1.134
Discovery of methylated circulating DNA biomarkers for comprehensive non-invasive monitoring of treatment response in metastatic colorectal cancer 1.048
Higher metastatic efficiency of KRas G12V than KRas G13D in a colorectal cancer model 855
Tracking a CAD-ALK gene rearrangement in urine and blood of a colorectal cancer patient treated with an ALK inhibitor 691
Efficacy of NEDD8 Pathway Inhibition in Preclinical Models of Poorly Differentiated, Clinically Aggressive Colorectal Cancer 654
A molecularly annotated platform of patient-derived xenografts (‘xenopatients’) identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer 627
Emergence of KRAS mutations and acquired resistance to anti EGFR therapy in colorectal cancer 564
EGFR blockade reverts resistance to KRAS G12C inhibition in colorectal cancer 562
A Genomic Analysis Workflow for Colorectal Cancer Precision Oncology 555
Digital PCR assessment of MGMT promoter methylation coupled with reduced protein expression optimises prediction of response to alkylating agents in metastatic colorectal cancer patients 545
Refining the selection of patients with metastatic colorectal cancer for treatment with temozolomide using proteomic analysis of O6-methylguanine-DNA-methyltransferase 523
Blockade of EGFR and MEK Intercepts Heterogeneous Mechanisms of Acquired Resistance to Anti-EGFR Therapies in Colorectal Cancer 492
The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets 487
Resistance to Anti-EGFR Therapy in Colorectal Cancer: From Heterogeneity to Convergent Evolution. 474
Bromodomain inhibition exerts its therapeutic potential in malignant pleural mesothelioma by promoting immunogenic cell death and changing the tumor immune-environment 461
Emergence of multiple EGFR extracellular mutations during cetuximab treatment in colorectal cancer 436
Costruzione di linee cellulari isogeniche per mutazioni associate al cancro e loro applicazione per approcci di farmacogenomica 412
Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients 366
MGMT methylation assessed by methyl-BEAMing technique is a prognostic and predictive biomarker in glioblastoma and metastatic colorectal cancer patients 357
Patient-derived xenografts and matched cell lines identify pharmacogenomic vulnerabilities in colorectal cancer 322
BCAM and LAMA5 Mediate the Recognition between Tumor Cells and the Endothelium in the Metastatic Spreading of KRAS Mutant Colorectal Cancer 318
INHIBITION OF MEK AND PI3K/MTOR SUPPRESSES TUMOR GROWTH BUT DOES NOT CAUSE TUMOR REGRESSION IN PATIENT-DERIVED XENOGRAFTS OF RAS-MUTANT COLORECTAL CARCINOMAS 304
Parallel Evaluation of Circulating Tumor DNA and Circulating Tumor Cells in Metastatic Colorectal Cancer 294
Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer 286
BRAF V600E is a determinant of sensitivity to proteasome inhibitors. 271
Amplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer. 268
Intrinsic Resistance to MEK Inhibition in KRAS Mutant Lung and Colon Cancer through Transcriptional Induction of ERBB3. 247
RET fusions in a small subset of advanced colorectal cancers at risk of being neglected 246
KRAS gene amplification in colorectal cancer and impact on response to EGFR-targeted therapy. 243
Vertical suppression of the EGFR pathway prevents onset of resistance in colorectal cancers 238
Retrospective multicenter study investigating the role of targeted next-generation sequencing of selected cancer genes in mucinous adenocarcinoma of the lung 221
Exploiting DNA repair defects in colorectal cancer 221
PTPN11 Is a Central Node in Intrinsic and Acquired Resistance to Targeted Cancer Drugs 219
Temozolomide treatment alters mismatch repair and boosts mutational burden in tumor and blood of colorectal cancer patients 214
Oncogenic Activation of the RAS/RAF Signaling Pathway Impairs the Response of Metastatic Colorectal Cancers to Anti– Epidermal Growth Factor Receptor Antibody Therapies 213
TGF-α and amphiregulin paracrine network promotes resistance to EGFR blockade in colorectal cancer cells. 208
VEGF blockade enhances the antitumor effect of BRAFV600E inhibition 205
Liquid biopsy: monitoring cancer-genetics in the blood 199
Evolving neoantigen profiles in colorectal cancers with DNA repair defects 199
A Subset of Colorectal Cancers with Cross-Sensitivity to Olaparib and Oxaliplatin 195
Acquired resistance to EGFR-targeted therapies in colorectal cancer. 194
Molecular landscape of acquired resistance to targeted therapy combinations in BRAF mutant colorectal cancer 192
The cholesterol biosynthesis enzyme oxidosqualene cyclase is a new target to impair tumour angiogenesis and metastasis dissemination 190
Homeobox B9 mediates resistance to anti-VEGF therapy in colorectal cancer patients 186
Acquired resistance to the TRK inhibitor entrectinib in colorectal cancer 183
Neuropilin-1 upregulation elicits adaptive resistance to oncogene-targeted therapies 183
Emergence of MET hyper-amplification at progression to MET and BRAF inhibition in colorectal cancer 160
Small nucleolar RNAs determine resistance to doxorubicin in human osteosarcoma 158
Adipocytes sustain pancreatic cancer progression through a non-canonical WNT paracrine network inducing ROR2 nuclear shuttling 157
Colorectal cancer early methylation alterations affect the crosstalk between cell and surrounding environment, tracing a biomarker signature specific for this tumor 157
RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells. 156
Targeting oncogenic serine/threonine-protein kinase BRAF in cancer cells inhibits angiogenesis and abrogates hypoxia 155
Mutation-Enrichment Next-Generation Sequencing for Quantitative Detection of KRAS Mutations in Urine Cell-Free DNA from Patients with Advanced Cancers 150
Radiologic and Genomic Evolution of Individual Metastases during HER2 Blockade in Colorectal Cancer 145
Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer 142
A Vulnerability of a Subset of Colon Cancers with Potential Clinical Utility 141
Kras mutations and resistance to anti-egfr treatment 139
Mouse models of Kras mutant colorectal cancer: valuable GEMMs for drug testing? 132
ISOGENIC HUMAN CELL LINES COMPRISING MUTATED CANCER ALLELES AND PROCESS USING THE CELL LINES 128
Reliance upon ancestral mutations is maintained in colorectal cancers that heterogeneously evolve during targeted therapies 127
Knock-in of oncogenic mutations in human somatic cells as a tool to identify genoselective compounds 125
The in vitro effect of gefitinib ('Iressa') alone and in combination with cytotoxic chemotherapy on human solid tumours 124
Anti-EGFR Antibody Therapy Based on an Increased Copy Number of the EGFR Gene in Tumor Tissues 119
Fibroblast Growth Factor Receptor (FGFR)3 sustains acquired resistance to trastuzumab in gastric cancer patients 115
Vitamin C Restricts the Emergence of Acquired Resistance to EGFR-Targeted Therapies in Colorectal Cancer 115
Tumor MGMT promoter hypermethylation changes over time limit temozolomide efficacy in a phase II trial for metastatic colorectal cancer 111
Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study 111
Abstract 1163: Microenvironment targets in KRAS-mutated metastatic colorectal cancer 110
Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus. 110
EMERGENCE OF KRAS MUTATIONS AND ACQUIRED RESISTANCE TO ANTI EGFR THERAPY IN COLORECTAL CANCER 109
MET-driven resistance to dual EGFR and BRAF blockade may be overcome by switching from EGFR to MET inhibition in BRAF mutated colorectal cancer 109
Unveiling of BRAF V600E Mutant Cells Sensitivity to Proteasome Inhibitors Using an Isogenic Cell Based Screening 107
Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer 106
Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. 103
BRAF V600E confers resistance to cetuximab or panitumumab metastatic colorectal cancer 101
Acquired Resistance to Anti EGFR Therapy in Colorectal Cancer and Paracrine Protection by KRAS Mutated Cells 101
Integrated molecular dissection of the epidermal growth factor receptor (EGFR) oncogenic pathway to predict response to EGFR-targeted monoclonal antibodies in metastatic colorectal cancer 100
Climbing RAS, the Everest of Oncogenes. 99
High Circulating Methylated DNA Is a Negative Predictive and Prognostic Marker in Metastatic Colorectal Cancer Patients Treated With Regorafenib. 96
Modeling tumor progression by the sequential introduction of genetic alterations into the genome of human normal cells 95
Replacement of normal with mutant alleles in the genome of normal human cells unveils mutation-specific drug responses 95
Cancer cell adaptation to chemotherapy 94
Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer 93
Kinase mutations in cancer: chinks in the enemy's armour? 92
Knock in of cancer mutations in human cells predicts pharmacologicalresponse to targeted therapies 88
The chemosensitivity profile of retinoblastoma 88
Outcome of ATP-based tumor chemosensitivity assay directed chemotherapy in heavily pre-treated recurrent ovarian carcinoma 88
Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer 88
Cisplatin, doxorubicin and paclitaxel induce mdr1 gene transcription in ovarian cancer cell lines 87
RAF Inhibitors 86
Biomarkers Predicting Clinical Outcome of Epidermal Growth Factor Receptor-Targeted Therapy in Metastatic Colorectal Cancer 83
Werner helicase is a synthetic-lethal vulnerability in Mismatch Repair-Deficient Colorectal Cancer Refractory to Targeted Therapies, Chemotherapy and Immunotherapy 83
Targeting the DNA Damage Response Pathways and Replication Stress in Colorectal Cancer 81
Transfection and DNA-Mediated Gene Transfer 80
Totale 38.152
Salva come PNG Salva come JPEG
Categoria #
all - tutte 75.799
article - articoli 0
book - libri 0
conference - conferenze 4.288
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 80.087
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20204.423 0 0 327 553 411 670 438 366 507 466 388 297
2020/20216.101 302 300 463 537 539 507 611 393 566 581 429 873
2021/20227.343 814 822 767 942 470 399 521 464 530 366 680 568
2022/20236.609 484 435 407 512 443 875 512 483 1.146 348 528 436
2023/20245.896 532 508 481 474 543 532 396 506 183 614 549 578
2024/20251.187 414 517 256 0 0 0 0 0 0 0 0 0
Totale 40.753